A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Revance Therapeutics
- 01 Apr 2025 Status changed from recruiting to completed.
- 21 May 2024 Status changed from not yet recruiting to recruiting.
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting, according to a Revance Therapeutics media release.